Selank: heptapeptide anxiolytic, GABAergic modulation, and the Russian research tradition

Selank, occasionally cataloged as TP-7, is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a stabilized analogue of tuftsin — a natural tetrapeptide fragment of the immunoglobulin G heavy chain with known immunomodulatory and behavioral effects. Selank extends the tuftsin sequence with three additional residues (Pro-Gly-Pro), which confer dramatically improved enzymatic stability and allow clinically meaningful duration of action from a single intranasal dose.

Unlike most peptide research compounds, Selank has an unusually developed clinical literature. It was approved for clinical use in Russia in 2009 for the treatment of generalized anxiety disorder and neurasthenia, following a comparative trial against medazepam [3]. This does not alter its research-use-only status in most jurisdictions, but it does provide an atypically rich human-subject literature compared to other compounds in its class.

The central mechanistic finding for Selank is modulation of the GABAergic system without direct binding to the benzodiazepine site on the GABA-A receptor. Volkova and colleagues (2016) demonstrated that Selank administration altered the expression of a panel of GABA-related genes in rat hippocampus, including genes encoding GABA-A receptor subunits and GABA-metabolizing enzymes [4]. This transcriptional footprint is distinct from the acute-allosteric profile of benzodiazepines and provides a theoretical basis for the observation that Selank produces anxiolysis without sedation, ataxia, or withdrawal.

A second mechanistic axis is monoaminergic. Semenova and colleagues reported that Selank administration affected serotonin and dopamine metabolism in rat brain regions associated with anxiety and reward — notably the hippocampus and the frontal cortex [2]. Kozlovskaya et al. described behavioral effects consistent with modulation of stress-adaptive systems in a series of open-field and conflict paradigms [1].

A third, and sometimes overlooked, axis is immunomodulation. Because Selank is derived from tuftsin, it retains some immunological activity. Uchakina and colleagues reported altered cytokine profiles in patients with anxiety-asthenic disorders treated with Selank, with particular effects on interleukin-6 and interferon-γ balance [5]. This provides a speculative rationale for observations of improved subjective well-being that exceed what would be expected from pure anxiolysis.

Transcriptomic profiling by Kolomin et al. identified hundreds of differentially expressed genes in the rat hippocampus following Selank administration, with particular enrichment in pathways related to synaptic transmission, inflammation, and protein metabolism [6].

Preclinical behavior. In rodent models of anxiety — elevated plus maze, open field, conflict drinking — Selank produces anxiolytic effects comparable to reference benzodiazepines at the behavioral level, but without the locomotor suppression or muscle-relaxant effects typically seen with benzodiazepines [1, 2]. This dissociation between anxiolysis and sedation is a recurring theme in the preclinical literature.

Human trials. Zozulia et al. (2008) reported a clinical comparison of Selank monotherapy against medazepam in patients with generalized anxiety disorder and neurasthenia, with comparable efficacy on standard anxiety scales and superior side-effect profile [3]. Medvedev et al. (2015) described combination use in anxiety disorders with favorable results [7]. These trials are Russian-language and are not indexed in all Western databases, which contributes to the perception of Selank as understudied despite the actual volume of human data.

Cognitive endpoints. Some reports describe mild improvements on attention and short-term memory tasks in healthy subjects under conditions of fatigue or stress, though these are secondary endpoints rather than primary study objectives. The framing of Selank as a “nootropic” in the Western grey literature is partially an extrapolation from this secondary signal.

Safety. The Russian clinical literature consistently reports a benign safety profile with no observed dependence or withdrawal, but pharmacovigilance data of the scale conducted for Western pharmaceuticals does not exist.

Selank is the canonical intranasal research peptide. The majority of published clinical studies used nasal drops or atomized sprays as the delivery route, typically administered as a 0.15% aqueous solution [3, 7]. This is a contrast to many other research peptides where intranasal administration is an extrapolation from other-route data; for Selank, nasal is the studied route.

The pharmacokinetic rationale aligns with the broader nasal-peptide literature. Selank is a small, proline-stabilized heptapeptide with acceptable solubility and absorption characteristics for the respiratory epithelium. Onset of subjective effects is typically reported within 15-30 minutes; duration of anxiolytic effect after a single dose is reported in the range of several hours, with cumulative effects over multi-day protocols.

For sourcing research-grade Selank under HPLC-verified purity with batch-matched certificates, the catalog entry is at /products/selank-nasal-spray.

In research protocol design, Selank is typically studied either alone or in combination with peptides targeting orthogonal CNS systems. Commonly discussed pairings:

• Semax— the other headline product of the Russian peptide research program. Semax is melanocortin-derived and primarily studied for neurotrophic and cognitive endpoints, which are orthogonal to Selank’s GABAergic/anxiolytic profile. Researchers typically separate dosing windows rather than co-administering. See our Semax entry for the mechanistic rationale.
• BPC-157 — mechanistically unrelated (angiogenic repair vs. GABAergic modulation) and generally considered compatible in protocol design. See the BPC-157 entry.
• Benzodiazepines, alcohol, other GABAergic compounds — this is the pairing to be most cautious about in protocol design. Selank’s GABAergic footprint is transcriptional and indirect, but the interaction space with direct GABA-A ligands is not well characterized. No formal interaction studies are published.